Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial

Blood blood.2025031313.

https://doi.org/10.1182/blood.2025031313

Published: 2025

Includes: Supplemental data

Journal Articles

Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study

Blood (2025) 146 (Supplement 1): 936.

https://doi.org/10.1182/blood-2025-936

Published: 2025

Journal Articles

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Noushin Farnoud, Kamal Menghrajani, Paola Guglielmelli, Christopher Famulare, Erin McGovern, Giuseppe Gaetano Loscocco, Andriy Derkach, Andrew Dunbar, Naseema Gangat, Vikas Gupta, Andrea Arruda, Taghi Manshouri, Srdan Verstovsek, Andrew Kuykendall, Vincent Ho, Auro Viswabandya, Joachim Deeg, Thomas Monahan, Tania Jain, Jeanne Palmer, Alla Keyzner, Aaron Gerds, Alexandra Gomez-Arteaga, Nikolai Podoltsev, Roni Tamari, Helen Ajufo, Satyajit Kosuri, Haris Ali, Idoroenyi Amanam, Jordan Chervin, Minal Patel, Jesús Gutiérrez-Abril, Sarun Sereewattanawoot, Juan Arango Ossa, Francesco Passamonti, Francesco Maura, Maymona Abdelmagid, Ahmed Abdelrheem, Yassin Bashir, Muhammad Yousuf, Animesh Pardanani, Kapila Viges, David Shoultz, Rick Winneker, Omar Abdel-Wahab, John Mascarenhas, Ronald Hoffman, Ross Levine, Elli Papaemmanuil, Alessandro Vannucchi, Ayalew Tefferi, Raajit Rampal

Blood (2025) 146 (Supplement 1): 2046.

https://doi.org/10.1182/blood-2025-2046

Published: 2025

Journal Articles

Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study

Blood (2025) 146 (Supplement 1): 4232.

https://doi.org/10.1182/blood-2025-4232

Published: 2025

Journal Articles

Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial

Blood (2025) 146 (Supplement 1): 2477.

https://doi.org/10.1182/blood-2025-2477

Published: 2025

Journal Articles

Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl

Blood (2025) 146 (Supplement 1): 5136.

https://doi.org/10.1182/blood-2025-5136

Published: 2025

Journal Articles

Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors

Blood (2025) 146 (Supplement 1): 6029.

https://doi.org/10.1182/blood-2025-6029

Published: 2025

Journal Articles

Trial in progress – a phase 1b trial of ivosidenib combined with ruxolitinib in IDH1-mutated advanced myeloproliferative neoplasms

Anand Patel, Theodore Karrison, Emily Dworkin, Rafael Madero-Marroquin, Austin Wesevich, Gregory Roloff, Caner Saygin, Mariam Nawas, Michael Drazer, Adam Duvall, Satyajit Kosuri, Michael Thirman, Wendy Stock, Richard Larson, Olatoyosi Odenike

Blood (2025) 146 (Supplement 1): 5608.

https://doi.org/10.1182/blood-2025-5608

Published: 2025

Journal Articles

Spiritual wellness and quality-of-life in adult patients with newly diagnosed acute leukemia receiving initial therapy: Patient-reported outcomes (PROs) from a prospective observational study

Hannah Johnston, Abigail Sneider, Tuula Pera, Rafael Madero-Marroquin, Austin Wesevich, Gregory Roloff, Mariam Nawas, Anand Patel, Michael Drazer, Adam Duvall, Satyajit Kosuri, Michael Thirman, Olatoyosi Odenike, Richard Larson, Caner Saygin, Wendy Stock, Christopher Daugherty

Blood (2025) 146 (Supplement 1): 6382.

https://doi.org/10.1182/blood-2025-6382

Published: 2025

Journal Articles

Primary efficacy analysis of phase II study investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Blood (2025) 146 (Supplement 1): 441.

https://doi.org/10.1182/blood-2025-441

Published: 2025

Journal Articles

Mechanistic basis of the acute safety profile of rese-cel, an autologous CD19-CAR T, in patients with autoimmune disease treated in four ongoing phase 1/2 clinical trials

Blood (2025) 146 (Supplement 1): 2336.

https://doi.org/10.1182/blood-2025-2336

Published: 2025

Journal Articles

Interim Results of a Phase II Study Investigating Dasatinib and Inotuzumab Ozogamicin-Based Induction for Newly-Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Anand Ashwin Patel, Adam S. Duvall, Caner Saygin, Howard Weiner, Emily Dworkin, Afsheen Noorani, Jamie Matthews, Rafael Madero Marroquin, Michael W Drazer, Mariam T. Nawas, Gregory W Roloff, Satyajit Kosuri, Michael J. Thirman, Richard A. Larson, Olatoyosi Odenike, Theodore Karrison, Wendy Stock

Blood (2024) 144 (Supplement 1): 1432.

https://doi.org/10.1182/blood-2024-193442

Published: 2024

Journal Articles

Outcomes of BCR::ABL1 -like B-Lineage Acute Lymphoblastic Leukemia in the Era of Novel Therapies

Blood (2024) 144 (Supplement 1): 5918.

https://doi.org/10.1182/blood-2024-208069

Published: 2024

Journal Articles

Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study

Blood (2023) 142 (Supplement 1): 3181.

https://doi.org/10.1182/blood-2023-173441

Published: 2023

Journal Articles

Impact of Investigational Microbiome Therapeutic SER-155 on Pathogen Domination: Initial Results from a Phase 1b Study in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)

Jonathan U. Peled, Marcel R.M. van den Brink, Doris M. Ponce, Satyajit Kosuri, Nandita Khera, Zachariah DeFilipp, Bina Tejura, David I Lichter, Mary-Jane Lombardo, Meghan Chafee, Jennifer R Wortman, Timothy Straub, Emily Walsh, Augustus Ge, David Lyttle, Brooke Hasson, Christopher Ford, Lisa von Moltke, Matthew Henn

Blood (2023) 142 (Supplement 1): 2198.

https://doi.org/10.1182/blood-2023-188885

Published: 2023

Journal Articles

Preliminary Safety Results of the Open-Label Phase of a 2-Part Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Cell Transplantation

Doris M. Ponce, Satyajit Kosuri, Nandita Khera, Zachariah Defilipp, David I Lichter, Jonathan U Peled, Marcel R.M. van den Brink, Kelly Brady, Matthew D Puhl, Gabrielle Glick, Brooke Hasson, Barbara H McGovern, Lisa von Moltke, Bina Tejura

Blood (2023) 142 (Supplement 1): 6994.

https://doi.org/10.1182/blood-2023-180119

Published: 2023

Journal Articles

A Phase 1b Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Stem Cell Transplantation

Doris M Ponce, Jonathan U Peled, Bindu Tejura, Christopher Ford, Marcel R M van den Brink, Mary Jane Lombardo, Satyajit Kosuri, Nandita Khera, Zachariah Defilipp, Lisa von Moltke

Blood (2022) 140 (Supplement 1): 10532–10533.

https://doi.org/10.1182/blood-2022-162386

Published: 2022

Journal Articles

Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)

Sameem Abedin, Mehdi Hamadani, Shernan G Holtan, Gary J. Schiller, Molly Gallogly, Edmund K. Waller, Satyajit Kosuri, Sunil H Abhyankar, Sarah M. Anand, Mahasweta Gooptu, Iming Cho, Simona Reed, Shih-Yao Lin, Jesse W Hall, Paul J Martin

Blood (2022) 140 (Supplement 1): 10495–10497.

https://doi.org/10.1182/blood-2022-163027

Published: 2022

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies

Blood (2022) 140 (Supplement 1): 10542–10544.

https://doi.org/10.1182/blood-2022-167098

Published: 2022

Journal Articles

Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results

Anand Ashwin Patel, MD, Joseph Heng, MD, Emily Dworkin, PharmD, Sarah Monick, MD, Benjamin A Derman, MD, Sandeep Gurbuxani, MBBS, PhD, Satyajit Kosuri, MD, Hongtao Liu, MD PhD, Michael Thirman, MD, Lucy A. Godley, Olatoyosi Odenike, MD, Richard A. Larson, MD, Wendy Stock, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-138967

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Orca-T versus allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial

Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study

Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial

Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl

Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors

Trial in progress – a phase 1b trial of ivosidenib combined with ruxolitinib in IDH1-mutated advanced myeloproliferative neoplasms

Spiritual wellness and quality-of-life in adult patients with newly diagnosed acute leukemia receiving initial therapy: Patient-reported outcomes (PROs) from a prospective observational study

Primary efficacy analysis of phase II study investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Mechanistic basis of the acute safety profile of rese-cel, an autologous CD19-CAR T, in patients with autoimmune disease treated in four ongoing phase 1/2 clinical trials

Interim Results of a Phase II Study Investigating Dasatinib and Inotuzumab Ozogamicin-Based Induction for Newly-Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Outcomes of BCR::ABL1 -like B-Lineage Acute Lymphoblastic Leukemia in the Era of Novel Therapies

Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study

Impact of Investigational Microbiome Therapeutic SER-155 on Pathogen Domination: Initial Results from a Phase 1b Study in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)

Preliminary Safety Results of the Open-Label Phase of a 2-Part Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Cell Transplantation

A Phase 1b Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Stem Cell Transplantation

Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)

Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies

Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only